Ivosidenib Clinical Trials (15 Recruiting)

Showing 1–16 of 16 trials

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)

Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953

Recruiting

Phase 1

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT05756777

Recruiting

Phase 2

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

CholangiocarcinomaIDH Mutation

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest40 enrolled8 locationsNCT07260175

Recruiting

Phase 1Phase 2

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Acute Myeloid LeukemiaHematopoietic and Lymphoid System NeoplasmMyelodysplastic Syndrome+3 more

M.D. Anderson Cancer Center96 enrolled4 locationsNCT03471260

Recruiting

Phase 2

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Memorial Sloan Kettering Cancer Center45 enrolled7 locationsNCT07392242

Recruiting

Phase 1

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia

M.D. Anderson Cancer Center125 enrolled1 locationNCT05010772

Recruiting

Phase 1Phase 2

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Institut de Recherches Internationales Servier52 enrolled37 locationsNCT06501625

Recruiting

Phase 2

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Biliary Tract Cancer

Peking Union Medical College Hospital300 enrolled1 locationNCT07282262

Recruiting

Phase 2

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid Leukemia+2 more

M.D. Anderson Cancer Center30 enrolled1 locationNCT04493164

Recruiting

Phase 1Phase 2

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center84 enrolled1 locationNCT04774393

Recruiting

Phase 1

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Myeloproliferative Neoplasms

University of Chicago18 enrolled1 locationNCT06291987

Recruiting

Not Applicable

MRD-positive AML Clinical Study

AML, Adult

Institute of Hematology & Blood Diseases Hospital, China120 enrolled1 locationNCT07131059

Recruiting

Phase 2

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Acute Myeloid Leukemia

Alice Mims125 enrolled1 locationNCT05401097

Recruiting

Phase 3

Personalized Medicine for Advanced Biliary Cancer Patients

Biliary Tract Neoplasms

UNICANCER800 enrolled69 locationsNCT05615818

Ivosidenib Clinical Trials

Ivosidenib as Post-HSCT Maintenance for AML

Study of SA+X in the Treatment of Newly Diagnosed AML

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

MRD-positive AML Clinical Study

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Personalized Medicine for Advanced Biliary Cancer Patients